Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis

  • participants needed
  • sponsor
    Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Updated on 6 February 2023
idiopathic pulmonary fibrosis


Jaktinib Dihydrochloride Monohydrate for idiopathic pulmonary fibrosis


This phase 2 study of Jaktinib Dihydrochloride Monohydrate, an oral inhibitor of JAK1 JAK2 and JAK3, is to assess efficacy and safety in patients with idiopathic pulmonary fibrosis.The study is a randomised,multicentre,double-blind,placebo-controlled,study.

Condition Pulmonary Fibrosis, usual interstitial pneumonia, Idiopathic Pulmonary Fibrosis
Treatment Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets, Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets, Placebo oral tablet and Acetylcysteine Effervescent Tablets
Clinical Study IdentifierNCT04312594
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Last Modified on6 February 2023

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note